News | November 04, 2024
Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Sustainability is integral to Biocon's business purpose
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Five batches across four programs of Biocon Academy participated in the graduation ceremony
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The RCSed's Court of Regents comprises a group of distinguished and accomplished individuals in their field
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Subscribe To Our Newsletter & Stay Updated
